CoviVac (Vietnam COVID-19 vaccine)
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
COVIVAC is a COVID-19 vaccine candidate developed by Institute of Vaccines and Medical Biologicals in Vietnam.[1][2][3]
Description[edit]
COVIVAC is a viral vector (non-replicating), egg-based, inactivated vaccine (whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018).[4] The vaccine requires two doses, the second one being administered 28 days after the first shot.[5]
Clinical trials[edit]
Phase I[edit]
On 21 January, the second Vietnam produced COVID-19 vaccine (COVIVAC) by Institute of Vaccine and Medical Biologicals (IVAC) has entered a human-clinical trial, nearly two months ahead of schedule. COVIVAC vaccine has been studied by IVAC since May 2020, has carried out pre-clinical trials in India, US and Vietnam, the results show safety and efficacy in experiment, fully meeting the conditions for conducting research with humans participants. The vaccine stability evaluation was conducted at Icahn School of Medicine at Mount Sinai, New York City.[6] Phase 1 recruited 120 healthy Vietnamese adult volunteers, aged 18–59.[7] On 15 March 2021, six volunteers were injected with the COVIVAC vaccine, at the Hà Nội Medical University. All 120 volunteers received the first dose, six of them received the second dose. Phase I will be completed on 15/5.[8] The research team recorded side effects from the volunteer's health, such as pain, fever, redness, headache, fatigue, muscle aches, and nausea. After 14 days infected second doses, the group of volunteers continued to get blood samples to test for antibodies.[9]
Phase II[edit]
Phase two clinical trials may start in June 2021 in Vu Thu district, Thai Binh province.[10]
References[edit]
- ^ "Second Việt Nam-produced COVID-19 vaccine to enter human trials this month". Vietnam News. 5 January 2021.
- ^ "Human trials start on second Vietnam-produced COVID-19 vaccine". Nhân Dân. 15 March 2021.
- ^ "A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC". clinicaltrials.gov. United States National Library of Medicine. Retrieved 9 April 2021.
- ^ "Draft landscape and tracker of COVID-19 candidate vaccines". WHO. 30 March 2021.
- ^ "Cập nhật tiến độ thử nghiệm lâm sàng 2 vắc xin phòng COVID-19 "made in" Việt Nam". Sức khỏe & Đời sống/Ministry of Health (Vietnam). 7 April 2021.
- ^ "Khởi động thử nghiệm vaccine phòng Covid-19 thứ 2 của Việt Nam" (in Vietnamese). Nhân Dân. 21 January 2021. Retrieved 25 January 2021.
- ^ "6 tình nguyện viên đầu tiên tiêm thử nghiệm vaccine COVIVAC vào sáng mai (15/3)". VOV. 14 March 2021.
- ^ "6 tình nguyện viên tiêm thử nghiệm vaccine COVIVAC phòng COVID-19 của Việt Nam". Vietnam MOH.
- ^ "Tốc độ thử nghiệm Covivac nhanh hơn dự kiến". VnExpress.
- ^ "100% người tiêm thử Nanocovax sinh miễn dịch tốt". VnExpress.
External links[edit]
 |
Scholia has a profile for CoviVac (Q106204649). |
